482 related articles for article (PubMed ID: 26863983)
1. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
[TBL] [Abstract][Full Text] [Related]
2. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
Li H; Bogyo M; da Fonseca PC
FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
[TBL] [Abstract][Full Text] [Related]
3. Plasmodium berghei K13 Mutations Mediate
Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
[TBL] [Abstract][Full Text] [Related]
4. Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity.
Li H; Ponder EL; Verdoes M; Asbjornsdottir KH; Deu E; Edgington LE; Lee JT; Kirk CJ; Demo SD; Williamson KC; Bogyo M
Chem Biol; 2012 Dec; 19(12):1535-45. PubMed ID: 23142757
[TBL] [Abstract][Full Text] [Related]
5. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.
Li H; Tsu C; Blackburn C; Li G; Hales P; Dick L; Bogyo M
J Am Chem Soc; 2014 Oct; 136(39):13562-5. PubMed ID: 25226494
[TBL] [Abstract][Full Text] [Related]
6. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
[TBL] [Abstract][Full Text] [Related]
7. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
[TBL] [Abstract][Full Text] [Related]
8. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
[TBL] [Abstract][Full Text] [Related]
9. Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking.
Subramaniam S; Mehrotra M; Gupta D
Comb Chem High Throughput Screen; 2011 Dec; 14(10):898-907. PubMed ID: 21843142
[TBL] [Abstract][Full Text] [Related]
10. High-resolution cryo-EM proteasome structures in drug development.
Morris EP; da Fonseca PCA
Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
[TBL] [Abstract][Full Text] [Related]
11. Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.
Yoo E; Stokes BH; de Jong H; Vanaerschot M; Kumar T; Lawrence N; Njoroge M; Garcia A; Van der Westhuyzen R; Momper JD; Ng CL; Fidock DA; Bogyo M
J Am Chem Soc; 2018 Sep; 140(36):11424-11437. PubMed ID: 30107725
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Asparagine Ethylenediamines as Anti-malarial
Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
[TBL] [Abstract][Full Text] [Related]
13. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
Hsu HC; Li D; Zhan W; Ye J; Liu YJ; Leung A; Qin J; Crespo B; Gamo FJ; Zhang H; Cui L; Roth A; Kirkman LA; Li H; Lin G
Nat Commun; 2023 Dec; 14(1):8302. PubMed ID: 38097652
[TBL] [Abstract][Full Text] [Related]
14. Design of proteasome inhibitors with oral efficacy in vivo against
Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Proteasome Inhibitors as Antimalarial Drugs.
Le Chapelain C; Groll M
Angew Chem Int Ed Engl; 2016 May; 55(22):6370-2. PubMed ID: 27079849
[TBL] [Abstract][Full Text] [Related]
16. Chemogenomic Profiling of a Plasmodium falciparum Transposon Mutant Library Reveals Shared Effects of Dihydroartemisinin and Bortezomib on Lipid Metabolism and Exported Proteins.
Pires CV; Oberstaller J; Wang C; Casandra D; Zhang M; Chawla J; Adapa SR; Otto TD; Ferdig MT; Rayner JC; Jiang RHY; Adams JH
Microbiol Spectr; 2023 Jun; 11(3):e0501422. PubMed ID: 37067430
[TBL] [Abstract][Full Text] [Related]
17. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.
Deni I; Stokes BH; Ward KE; Fairhurst KJ; Pasaje CFA; Yeo T; Akbar S; Park H; Muir R; Bick DS; Zhan W; Zhang H; Liu YJ; Ng CL; Kirkman LA; Almaliti J; Gould AE; Duffey M; O'Donoghue AJ; Uhlemann AC; Niles JC; da Fonseca PCA; Gerwick WH; Lin G; Bogyo M; Fidock DA
Cell Chem Biol; 2023 May; 30(5):470-485.e6. PubMed ID: 36963402
[TBL] [Abstract][Full Text] [Related]
18. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.
Kirkman LA; Zhan W; Visone J; Dziedziech A; Singh PK; Fan H; Tong X; Bruzual I; Hara R; Kawasaki M; Imaeda T; Okamoto R; Sato K; Michino M; Alvaro EF; Guiang LF; Sanz L; Mota DJ; Govindasamy K; Wang R; Ling Y; Tumwebaze PK; Sukenick G; Shi L; Vendome J; Bhanot P; Rosenthal PJ; Aso K; Foley MA; Cooper RA; Kafsack B; Doggett JS; Nathan CF; Lin G
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6863-E6870. PubMed ID: 29967165
[TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationship Studies of Antimalarial
Zhang H; Ginn J; Zhan W; Leung A; Liu YJ; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Michino M; Yukawa T; Chelebieva S; Tumwebaze PK; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Liverton N; Foley M; Meinke PT; Nathan CF; Kirkman LA; Lin G
J Med Chem; 2023 Jan; 66(2):1484-1508. PubMed ID: 36630286
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium chabaudi chabaudi and P. falciparum: inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin.
Nankya-Kitaka MF; Curley GP; Gavigan CS; Bell A; Dalton JP
Parasitol Res; 1998 Jul; 84(7):552-8. PubMed ID: 9694371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
